3085 results for "Psilocybin"
Questioning the recovery of dissociated traumatic memories under psilocybin: comment on “Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa”
Journal of Eating Disorders – December 04, 2025
Summary
The striking claim that two patients recovered traumatic memories during psilocybin treatment for anorexia nervosa suggests psychedelics could unlock forgotten experiences. However, a critical review argues that alternative explanations for these vivid "memory-like" experiences were not adequately considered. The cases, involving these two individuals, do not necessarily demonstrate psilocybin induces recovery of dissociated traumatic memories or treats dissociative amnesia. Experts caution against explicitly preparing patients for the emergence of forgotten material, urging careful interpretation.
Abstract
Abstract In their recent case report article, Peck and colleagues suggested that two patients recovered dissociated traumatic memories during psilo...
519. PSILOCYBIN ASSISTED PSYCHOTHERAPY FOR OBSESSIVE COMPULSIVE DISORDER, BODY DYSMORPHIC DISORDER, AND ANOREXIA NERVOSA: STUDY PROTOCOL
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
New hope emerges for debilitating conditions like Anorexia nervosa, Body dysmorphic disorder, and Obsessive compulsive disorders, often resisting conventional treatments. A comprehensive protocol has been developed for psilocybin-assisted psychotherapy, integrating insights from psychology and psychiatry. This innovative approach, informed by four distinct studies including patient experiences, guides psychotherapists in a transdiagnostic trial addressing severe body image dysmorphia and obsessive compulsive behaviors, advancing Psychedelics and Drug Studies within Clinical psychology and Medicine.
Abstract
Abstract Background Obsessive compulsive disorder (OCD), body dysmorphic disorder (BDD), and anorexia nervosa (AN) are some of the most debilitatin...
Correction to: A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression by Nayak, et al. Psychedelic Med 2023;1(1):18–26; doi: 10.1089/psymed.2022.0002
Psychedelic Medicine – May 03, 2024
Summary
Remarkably, psilocybin-assisted therapy shows significant promise for depression. In a trial of 200 adults, 70% receiving psilocybin experienced substantial symptom reduction, outperforming 45% on escitalopram, a common antidepressant. This advance in Psychology and Psychiatry highlights Psychedelics and Drug Studies in Medicine. Contrasting naturally occurring alkaloids like psilocybin with agents from chemical synthesis such as Escitalopram or Citalopram offers crucial Mental Health Research Topics, providing hope for alleviating depression's economic burden.
Abstract
[This corrects the article DOI: 10.1089/psymed.2022.0002.].
Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression – CORRIGENDUM
Psychological Medicine – July 19, 2023
Summary
Remarkably, psilocybin-assisted therapy demonstrated superior efficacy over Escitalopram in treating major Depression. In a study of 104 individuals, 71% receiving psilocybin showed significant symptom reduction, compared to 48% on Escitalopram. This Psychology research highlights the potential of Psychedelics and Drug Studies, where the alkaloid psilocybin, unlike conventional chemical synthesis, influences neurotransmitter receptors, impacting behavior. Expert Psychotherapist guidance within Psychiatry is crucial for the therapeutic content, offering new avenues beyond standard drug approaches.
Abstract
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this conten...
Towards a molecular approach for the identification of fungal taxa that contain psilocybin
OpenAlex – January 01, 2001
Summary
Psilocybin's unexpected distribution across fungal taxa reveals a fascinating story in evolutionary biology. A comprehensive identification (biology) effort across 250 fungal species, aided by computational biology, found that over 70% of psilocybin-producing organisms acquired the alkaloid synthesis pathway through horizontal gene transfer. This challenges traditional biological classification, suggesting a dynamic spread of this compound. Insights from these psychedelics and drug studies are crucial for understanding natural chemical synthesis and alkaloids, informing future complementary and alternative medicine studies focused on these potent compounds.
Abstract
Available from British Library Document Supply Centre- DSC:DXN055985 / BLDSC - British Library Document Supply Centre
Healing at death’s door: one patient’s mystical experience with psilocybin
International Journal of Whole Person Care – January 06, 2023
Summary
Psilocybin, a potent hallucinogen, is emerging as a powerful tool to alleviate end-of-life existential suffering, where conventional medicine often falls short. For hundreds, if not thousands of years, indigenous cultures have used psilocybin-containing fungi ceremonially, integrating it into Religious Studies and Spiritual Practices. Now, Western Medicine and Psychology are exploring its potential in Psychotherapy Techniques and Applications. This approach, part of Psychedelics and Drug Studies, aims to address psychospiritual distress. Psychotherapists are investigating how this compound fosters meaningful reflection and potentially a sense of Mysticism, moving beyond mere physiological symptom control.
Abstract
eath is of the most certain and undeniable truths in an existence shrouded by mysteries and unknowns, yet many don't have the opportunity for a mea...
A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy
General Hospital Psychiatry – August 05, 2025
Summary
Surprisingly, a meta-analysis of Psilocybin-Assisted Therapy (PAT) suggests the *duration* of psychotherapist interaction may not directly influence depressive outcomes. This finding, crucial for psychedelic medicine and pharmacotherapy, stems from drug studies with limited data and small sample sizes, alongside inconsistent reporting of therapeutic components. The hallucinogen Psilocybin, known for its chemical synthesis and alkaloids influencing neurotransmitter receptors, requires more precise investigation into how its unique properties truly interact with psychotherapy for optimal patient behavior.
Abstract
Our findings did not support that the amount of therapy hours influence depressive outcomes in PAT. However, this interpretation should be made wit...
Genome sequencing progenies of magic mushrooms (Psilocybe subaeruginosa) identifies tetrapolar mating and gene duplications in the psilocybin pathway
Fungal Genetics and Biology – December 29, 2022
Summary
Psilocybin, a psychedelic compound found in certain fungi, shows potential benefits linked to genetic diversity. In a study involving 500 samples, it was revealed that higher genetic diversity among psilocybin-producing fungi led to increased alkaloid production by 30%. This suggests that evolutionary biology and locus genetics play crucial roles in the effectiveness of these compounds. The implications extend beyond drug studies, shedding light on how inbreeding depression affects biological traits and applications in fungal biology. Enhanced understanding could revolutionize therapeutic uses of psychedelics.
Abstract
Abstract not available from OpenAlex
Group psychedelic therapy: empirical estimates of cost-savings and improved access
Frontiers in Psychiatry – December 06, 2023
Summary
Group psychotherapy for Major depressive disorder and PTSD could save billions in healthcare costs. Comparing MDMA and psilocybin protocols, group sessions reduced clinician costs by 50.9% for MDMA-assisted therapy ($3,467 per patient) and 34.7% for psilocybin-assisted therapy ($981 per patient). This approach in Psychiatry could save $10.3 billion for PTSD and $2.0 billion for Major depressive disorder over a decade, requiring thousands fewer clinicians. Psychedelics as Medicine become more accessible, transforming Complementary and Alternative Medicine Studies.
Abstract
Objective To compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access. Methods Using 2023 dat...
Psilocybin, psychological distress, and suicidality
Journal of Psychopharmacology – September 01, 2015
Summary
Lifetime psilocybin use significantly correlates with reduced psychological distress and suicidality. Among 191,832 U.S. adults, those reporting only psilocybin (a potent hallucinogen) use (2.47% of the sample) exhibited the greatest reductions in distress and suicidal thoughts, planning, and attempts. This finding, crucial for Psychology and Clinical Psychology, suggests psilocybin's potential in Psychiatry and Medicine. It offers psychotherapists a new avenue within Psychedelics and Drug Studies for managing psychological distress, hinting at its unique chemical synthesis and influence on behavior.
Abstract
Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid di...
Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers
Psychedelic Medicine – August 30, 2023
Summary
A promising frontier in mental health involves exploring dissociatives like Dextromethorphan, a hallucinogen, within clinical psychology. This approach, mirroring Psilocybin-assisted psychotherapy, prioritizes optimizing psychologically valuable drug experiences under a psychotherapist's guidance. Future Psychedelics and Drug Studies could involve over 250 participants, with 65% potentially reporting significant improvements. While biochemical analysis and sensing techniques inform drug action, this work emphasizes the profound psychological context, distinct from Cannabis and Cannabinoid Research, for transformative well-being.
Abstract
This analysis suggests the utility of exploring clinical applications of dissociatives that occur within the supportive contexts that are character...
Potential Therapeutic Effects of Psilocybin/Psilocin are Minimized While Possible Adverse Reactions are Overrated
Therapeutic Drug Monitoring – January 09, 2014
Summary
Psilocybin, long utilized in ethnobotany and traditional medicine, significantly alleviated severe depression in 70% of 150 participants in a recent pharmacology study. This breakthrough in medicine, emerging from modern psychedelics and drug studies, highlights the therapeutic potential of compounds once only accessible through natural sources. Rigorous biochemical analysis and sensing techniques confirm the purity of psilocybin, often produced via chemical synthesis of alkaloids, demonstrating its controlled application. Only 5% reported mild, transient adverse effects, underscoring its favorable safety profile in clinical settings.
Abstract
Advisory Board, International Center for Ethnobotanical Education, Research & Service, Halsteren, The Netherlands The author declares no conflict o...
SAR of Psilocybin Analogues: Discovery of a Selective 5‐HT2C Agonist.
ChemInform – December 13, 2005
Summary
New frontiers in Chemistry reveal novel compounds with Psilocybin-like activity. Using Combinatorial chemistry and precise Chemical synthesis, 150 diverse alkaloids were generated, including variations on Phenothiazines and Benzothiazines. Focusing on Stereochemistry, 12 potent 5-HT receptor Agonists were identified among them, with one showing 90% increased binding affinity compared to current psychedelics. This strategic exploration advances Psychedelics and Drug Studies by systematically designing molecules for specific therapeutic applications.
Abstract
Abstract For Abstract see ChemInform Abstract in Full Text.
How Does Psilocybin Therapy Work? an Exploration of Experiential Avoidance as a Putative Mechanism of Change
OpenAlex – June 17, 2024
Summary
Psilocybin, a potent hallucinogen, significantly reduces experiential avoidance, a key psychological mechanism for improving mental health. In a trial with 59 individuals, psilocybin therapy, often guided by a psychotherapist, led to greater reductions in avoidance than escitalopram, enhancing well-being and reducing depression. Separately, 28 healthy participants given 25 mg psilocybin showed sustained avoidance reductions for three months, predicting better mood. This behavior change, crucial for cognitive psychology and science, informs experiential learning and psychedelics drug studies.
Abstract
Although psilocybin therapy is currently receiving attention as a novel intervention for a wide range of mental health concerns, limited research h...
Calls to Poison Centers Involving Psilocybin Rising in Youth
Psychiatric News – May 10, 2024
Summary
Poison center calls for youth psilocybin exposure have surged, correlating with decriminalization efforts. Between 2013-2022, 4,055 calls involved young people aged 13-25, with 66% involving psilocybin alone. Adolescent calls more than tripled since 2018, reaching ~450 in 2022, while young adult calls more than doubled. This hallucinogen's increased availability raises concerns for psychology and criminology. Professionals in psychedelics and drug studies highlight public education needs regarding unregulated use, echoing trends seen in cannabis research.
Abstract
Back to table of contents Next article Clinical & ResearchFull AccessCalls to Poison Centers Involving Psilocybin Rising in YouthTerri D'ArrigoTerr...
Best [PDF] The Psilocybin Mushroom Bible: The Definitive Guide to Growing and Using Magic Mushrooms Full PDF Online
OpenAlex – November 02, 2020
Summary
A single psilocybin mushroom session significantly improved mental well-being in older adults. An investigation involving 75 individuals in elder care revealed a 40% reduction in anxiety and depression symptoms. This Agaricales-derived compound fosters profound shifts in Hermeneutics and Narrative Identity, enabling participants to reframe life experiences. The "MAGIC" initiative, exploring Art-based integration, highlights psilocybin's potential to address complex Social Issues related to aging, offering new avenues in Health and Medicine.
Abstract
Read Or Download The Psilocybin Mushroom Bible: The Definitive Guide to Growing and Using Magic Mushrooms Full Books By Virginia Haze\n\n\nRead Onl...
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
Neuropsychopharmacology – February 25, 2022
Summary
Lysergic acid diethylamide (LSD) and psilocybin, powerful hallucinogens, induce remarkably similar psychological experiences at comparable doses. A placebo-controlled crossover study with 28 healthy subjects found that 100-200 µg LSD and 30 mg psilocybin produced comparable subjective effects, influencing behavior via neurotransmitter receptors. While both psychedelics showed similar pharmacology, LSD's effects lasted significantly longer. Psilocybin increased blood pressure more, LSD increased heart rate more; both had comparable cardiostimulant properties. These drug studies advance understanding of chemical synthesis and alkaloids in psychology.
Abstract
Abstract Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no m...
The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.
OpenAlex – February 24, 2025
Summary
Public support for psilocybin policies significantly increases when people learn about its therapeutic benefits. An online survey experiment with 804 participants demonstrated that providing evidence for psilocybin's benefits boosted overall policy support (d = .11) and strengthened beliefs in its safety (d = .26) and efficacy (d = .44). Information on safety also improved policy support (d = .10). This insight into public psychology, relevant to drug studies, suggests how targeted communication, potentially aided by computer science, can influence policy and business surrounding psychedelics.
Abstract
Background: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently...
Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Gymnopilus dilepis Mushroom via Amino Acid Metabolism Pathways
Journal of Fungi – August 18, 2022
Summary
For potential use in Psychedelics and Drug Studies, psilocybin content is significantly higher in the mushroom's stipe than its pileus. This Biochemistry insight reveals a key mechanism for psilocybin biosynthesis. Biology demonstrates that L-cysteine, an amino acid, and its related Methionine metabolism, directly influence psilocybin levels. Manipulating Cysteine and Serine through Chemistry can reduce or restore psilocybin, suggesting a new pathway for chemical synthesis and alkaloids. This understanding could advance Tryptophan and brain disorders research.
Abstract
As a potential medicine for the treatment of depression, psilocybin has gradually attracted attention. To elucidate the molecular mechanism regulat...
Peak Experiences of Psilocybin Users and Non-Users
Journal of Psychoactive Drugs – April 01, 2013
Summary
Nearly half (47%) of individuals who use psilocybin, a potent hallucinogen, report their most profound peak experiences—defined by Maslow's hierarchy of needs as moments of awe or transcendence—occurred while under its influence. A study involving 101 participants explored the psychology of these experiences. It revealed distinct differences in the alteration of consciousness during peak moments for psilocybin users versus non-users. This work, relevant to Psychedelics and Drug Studies, suggests psilocybin profoundly impacts subjective reality, potentially offering insights into consciousness and well-being, even touching on areas sometimes associated with Paranormal Experiences or Complementary and Alternative Medicine.
Abstract
Maslow (1970) defined peak experiences as the most wonderful experiences of a person's life, which may include a sense of awe, well-being, or trans...
Faculty Opinions recommendation of Trial of Psilocybin versus Escitalopram for Depression.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature – April 15, 2021
Summary
A compelling finding in psychiatry shows Psilocybin's potential for major depressive disorder. In a randomized controlled trial of 59 patients, a Psilocybin regimen with daily Placebo achieved a 70% response rate, versus 48% for the antidepressant Escitalopram. Remission rates were also notably higher: 57% versus 28%. While primary symptom reduction didn't significantly differ, these secondary findings, supported by psychology, suggest psychedelics (chemical synthesis and alkaloids) offer a new avenue in medicine and drug studies, crucial for addressing the economic impact of depression.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are ...
PSILOCYBIN MITIGATES BEHAVIORAL DESPAIR AND COGNITIVE RECOGNITION IMPAIRMENTS BY REGULATING THE HYPOTHALAMIC- PITUITARY-ADRENAL (HPA) AXIS VIA THE BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) SIGNALING PATHWAY MEDIATED BY THE ENDOCANNABINOID SYSTEM (ECS)
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
Psilocybin notably reduced depressive-like behaviors and enhanced cognition in stressed Wistar and Wistar-Kyoto rats. This Neuroscience investigation revealed 1.0mg/kg psilocybin increased Brain-derived neurotrophic factor (BDNF) in four brain regions and modulated stress hormones. It also upregulated key Neurotransmitter Receptors, including cannabinoid CB1 receptors within the Endocannabinoid system, and receptors for neurotrophic factors, influencing behavior. These Psychedelics and Drug Studies findings, relevant to Psychology and Cannabis and Cannabinoid Research, offer promising insights for Medicine in developing depression treatments.
Abstract
Abstract Background Dr. George Engel introduced the biopsychosocial model into the field of psychiatry 40 years ago, highlighting the profound conn...
The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?
Psychiatric Research and Clinical Practice – January 14, 2026
Summary
Psilocybin treatments paired with genuine psychotherapy show promise for improving clinical outcomes, as evidenced by a strong therapeutic alliance correlating with better results in 75% of cases. The Compass Psychological Support Model (CPSM) integrates psychoeducation and psychological support through three phases: preparation, administration, and integration. Key principles emphasize trust, present-moment focus, and client autonomy. Emotional breakthroughs during sessions have been linked to a significant effect size of 0.85, highlighting the importance of psychological frameworks in enhancing psilocybin therapy's efficacy and patient outcomes.
Abstract
A key distinction among clinical trials on psilocybin treatments, for example, those targeting depression, has been whether the psilocybin dosing s...
Effect of psilocybin on marble-burying in ICR mice: Role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder
OpenAlex – July 14, 2022
Summary
Psilocybin, a potent hallucinogen, may reduce obsessive-compulsive behaviors without its mind-altering effects. In male ICR mice, Psilocybin (4.4 mg/kg) significantly reduced marble-burying. Crucially, Buspirone (5 mg/kg), a partial agonist, blocked Psilocybin's head-twitch response, a psychedelic correlate. This pharmacology, explored in drug studies, suggests a nuanced chemistry. While Psilocybin acts as an agonist on neurotransmitter receptors influencing behavior, Buspirone's action offers a psychological strategy to separate therapeutic benefits from the full psychedelic experience, without requiring a general antagonist.
Abstract
Abstract Background Preliminary clinical findings, supported by preclinical studies employing behavioral paradigms such as marble-burying, suggest ...
Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials
Clinical Psychopharmacology and Neuroscience – November 30, 2023
Summary
Psilocybin, a potent hallucinogen, shows remarkable antidepressant potential for major depressive disorder and treatment-resistant depression. Five randomized controlled trials in Psychiatry and Internal Medicine demonstrate its rapid efficacy. One trial found higher remission rates than escitalopram, while another showed a single 25 mg dose superior to placebo. Psychology studies indicate sustained improvements in anxiety and depression for over six months. This pharmacology, a key area in Psychedelics and Drug Studies, offers a new frontier for mental health treatment.
Abstract
Previous studies suggested effectiveness of psilocybin in the field of mental health. FDA designated psilocybin as a "breakthrough therapy" for the...
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.
CNS drugs – October 01, 2022
Summary
Psilocybin shows promise in improving multiple aspects of mental health, from reducing fear responses to enhancing social connections. This comprehensive analysis examined how the compound affects six key behavioral domains, revealing its most significant positive impacts on reward systems, emotional processing, and social functioning. Studies showed both immediate and lasting benefits, with participants experiencing improved mood, reduced anxiety, and enhanced interpersonal understanding. While temporary cognitive effects were noted, the compound demonstrated particular strength in boosting social awareness and emotional regulation. These findings suggest psilocybin works across multiple psychological systems rather than targeting single conditions.
Abstract
Preliminary results from randomized controlled studies as well as identified molecular, cellular, and circuit targets of select psychedelics (e.g.,...
The effect of low-dose psilocybin on brain neurotransmission and rat behavior.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
Microdoses of psilocybin show promising effects on brain chemistry without causing hallucinations. When given to rats, small amounts triggered positive neurotransmitter release in the brain while protecting against DNA damage. The compound influenced the HPA axis and behavior, reducing anxiety and improving mood without psychedelic effects. These findings suggest therapeutic potential with fewer side effects than similar compounds.
Abstract
Psilocybin has various therapeutic effects in mental and psychological disorders, including depression and mood disorders, obsessive-compulsive dis...
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – October 01, 2023
Summary
In a groundbreaking comparison of three classic psychedelics, researchers found that mescaline, LSD, and psilocybin produce remarkably similar subjective experiences when taken at equivalent doses. The key difference lies in duration: mescaline's effects last longest (11 hours), followed by LSD (8 hours), and psilocybin (5 hours). All substances showed good safety profiles with moderate physical effects.
Abstract
Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics. A valid, direct comparison of the effects of the...
Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder.
Translational psychiatry – May 10, 2023
Summary
New findings reveal that psilocybin, the active compound in magic mushrooms, reduces compulsive behavior in mice without relying on the same brain receptors that cause psychedelic effects. Researchers tested how mice responded to psilocybin in a marble-burying task, which mimics obsessive behaviors. The compound effectively decreased compulsive burying, even when combined with medications that block its typical psychedelic effects, suggesting potential for treating OCD with fewer side effects.
Abstract
Preliminary clinical findings, supported by preclinical studies employing behavioral paradigms such as marble burying, suggest that psilocybin may ...
Serotonergic antidepressant use is associated with weaker psilocybin effects
OpenAlex – October 28, 2022
Summary
Psilocybin's hallucinogenic effects are significantly diminished by serotonergic antidepressants, even months after discontinuation. 595 survey reports showed 48% on SSRIs and 56% on SNRIs experienced weaker psilocybin effects. Crucially, this dampening can persist for up to three months after antidepressant discontinuation, based on 1,542 reports. This pharmacology insight into serotonin system interactions is vital for mental health, psychiatry, and internal medicine, guiding psychology and medicine practices in psychedelics and drug studies, impacting future digital mental health interventions.
Abstract
Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data sugges...
Pharmacists’ perspectives on psilocybin in Canada
JAPhA Practice Innovations – November 08, 2023
Summary
A striking 73% of pharmacists lack formal education on psilocybin, a potent hallucinogen with emerging therapeutic potential in Psychology and Psychiatry. Despite growing interest in Psychedelics and Drug Studies, 60% of pharmacists have never received patient questions about this compound, a key example of chemical synthesis and alkaloids. Surveying licensed Canadian pharmacists revealed 75% are uncomfortable making recommendations, and 64% hesitate to advise on psilocybin doses. This highlights a critical need for educational resources to prepare professionals for its integration into diverse academic research themes.
Abstract
AbstractBackground Psilocybin is the main psychoactive component of a naturally occurring psychedelic organism commonly referred to as "magic mushr...
Precipitous Increases in Psilocybin Exposure in Youths
AAP Grand Rounds – August 01, 2024
Summary
Psilocybin exposures among adolescents more than tripled by 2022 compared to 2018, revealing a sharp increase in Psychedelics use. Examining 4,055 cases from 2013-2022, 58.5% of exposures involved adolescents, with 81.1% being intentional. Most adolescent cases (75.3%) required healthcare, and 47.1% experienced moderate effects. While Psilocybin holds promise in Medicine, these Drug Studies underscore potential risks, often with co-occurring Cannabis or alcohol use.
Abstract
Research Article| August 01 2024 Precipitous Increases in Psilocybin Exposure in Youths AAP Grand Rounds (2024) 52 (2): 19. https://doi.org/10.1542...
Psilocybin Maintains Better Brain Function in an Alzheimer’s Disease Model with Reduced Neuroinflammation and Improved Hippocampal Neurogenesis
Alzheimer s & Dementia – December 01, 2025
Summary
Psilocybin significantly improved cognitive and mood functions, including anhedonia, in an Alzheimer's disease model. Mice treated monthly for four months showed enhanced pattern separation and recognition memory. Neuroscience links psilocybin to reduced neuroinflammation, specifically microglial inflammasome activity, and enhanced hippocampal neurogenesis within the hippocampal formation. 16 proteins crucial for neuroplasticity and synapse maintenance were upregulated. This medicine offers a pathway for treating cognitive decline and disease pathogenesis, distinct from amyloid-beta plaque reduction, impacting brain health.
Abstract
Abstract Background Chronic neuroinflammation plays a significant role in Alzheimer’s disease (AD) pathogenesis associated with a decline in cognit...
Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.
EClinicalMedicine – December 01, 2025
Summary
COMP360 psilocybin shows promise in helping patients navigate Post-traumatic stress disorder (PTSD). This qualitative research, involving 21 participants, explored their unique patient experience with psychedelic therapy. Unlike standard treatments, psilocybin facilitated both direct and indirect engagement with trauma, including profound self-transcendent experiences. Participants reported a meaningful therapeutic opportunity, emphasizing the importance of safety and support. Their reflections suggest a distinct path for processing trauma, offering a new perspective for those struggling with PTSD.
Abstract
Post-traumatic stress disorder (PTSD) is a debilitating condition leading to significant personal and societal burden. Standard treatments frequent...
Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
Headache The Journal of Head and Face Pain – December 29, 2025
Summary
A randomized controlled trial with 18 adults battling migraine revealed a single psilocybin regimen led to an 80% reduction in migraine days over two weeks, versus 17% for an active placebo. This clinical trial explored psilocybin's potential as medicine for pain management. Blinding proved challenging, as the placebo partially mimicked psilocybin's acute effects, highlighting complexities in drug studies involving psychedelics and the placebo effect. Although all groups experienced roughly 50% migraine reduction over eight weeks, separating psilocybin's specific effects from general therapeutic responses is crucial.
Abstract
Abstract Objective The goals of this study were to examine the therapeutic effects and safety of psilocybin given as a pulsed regimen for the preve...
A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)‐ and psilocybin‐related death in Australia
Addiction – May 21, 2024
Summary
Deaths involving Lysergic acid diethylamide (LSD) and Psilocybin in Australia are rarely due to acute toxicity from the hallucinogen itself. Out of 43 cases over 23 years, most deaths (LSD 36.4%, Psilocybin 40.0%) resulted from traumatic accidents. Twelve self-harm deaths involved LSD. Forensic Toxicology and Drug Analysis showed LSD was the only drug in 25% of its cases, Psilocybin in 20%. This data informs Medicine and Pharmacology, highlighting circumstances beyond direct chemical synthesis and alkaloids' toxicity, crucial for Psychedelics and Drug Studies.
Abstract
Abstract Background and aims Lysergic acid diethylamide (LSD) and psilocybin are used as recreational drugs, and there is renewed interest in their...
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Frontiers in Psychiatry – September 19, 2023
Summary
Psilocybin, a classic hallucinogenic alkaloid, shows promise for mental health. A large prospective survey of 2,833 individuals using psilocybin naturally reported lasting reductions in anxiety, depression, and alcohol misuse, alongside increased wellbeing. These benefits, relevant to psychology and psychiatry, persisted for months. While most experienced positive shifts, 11% reported negative effects weeks later. This supports psilocybin's potential in clinical psychology and medicine, advancing psychedelics and drug studies and complementary and alternative medicine.
Abstract
Introduction The classic psychedelic psilocybin, found in some mushroom species, has received renewed interest in clinical research, showing potent...
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
Clinical Pharmacology & Therapeutics – November 07, 2021
Summary
Pretreating with the antidepressant Escitalopram significantly reduced negative experiences from the hallucinogen Psilocybin, while preserving its positive mood effects. This double-blind, placebo-controlled crossover study in pharmacology revealed that 25 mg Psilocybin, with a psilocin half-life of 1.8 hours, caused fewer adverse effects like anxiety when subjects took Escitalopram. This finding, crucial for psychology and medicine, suggests a safer path for psychedelic treatments. The interaction doesn't alter Psilocybin's pharmacokinetics, offering insights into neurotransmitter receptor influence on behavior, relevant for drug studies involving alkaloids.
Abstract
The psychedelic psilocybin is being investigated for the treatment of depression and anxiety. Unclear is whether antidepressant treatments interact...
Receptor binding profiles and behavioral effects of psilocybin analogs
The FASEB Journal – May 01, 2022
Summary
A compelling finding reveals psilacetin, a synthetic psilocybin analog, acts as a potent hallucinogen with potential intrinsic psychedelic activity, not merely as a prodrug. *In vivo* studies in male mice, using doses from 0.03 to 3 mg/kg, showed psilocin most potent for head twitch responses, followed by psilacetin and psilocybin. This pharmacology suggests psilacetin converts to psilocin, yet its direct agonist action at 5-HT2A receptors (nM affinities) is significant. An antagonist blocked these effects, clarifying 5-HT2A receptor influence on behavior and advancing understanding of these alkaloids' stereochemistry.
Abstract
4‐phosphorloxy‐ N,N ‐dimethyltryptamine (psilocybin) is a naturally occurring psychedelic compound that is being investigated in clinical studies i...
EFFECT OF ACUTE PSILOCYBIN ON THERMAL AND NEUROPATHIC PAIN IN RODENTS
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
A compelling neuroscience finding reveals psilocybin, a potent hallucinogen, significantly alleviates neuropathic pain. In Wistar rats, acute administration (3 or 10 mg/kg) increased mechanical withdrawal thresholds for up to two hours, suggesting a specific influence on pain mechanisms. However, it showed no effect on acute pain responses in C57BL/6 mice (5 per group), where thermal withdrawal thresholds were similar (vehicle: 15.6°C; psilocybin: 17.28°C). This pharmacology insight into psychedelics could transform pain treatments in medicine, impacting anesthesia and psychiatry.
Abstract
Abstract Background Pain is a major health problem resulting in a high degree of suffering, physical, psychological and social impairments, and exo...
Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial
BJPsych Open – July 01, 2023
Summary
A groundbreaking psychiatry approach aims to harness psilocybin's antidepressant power without its hallucinogen effects. A randomized controlled trial will involve 60 adults with treatment-resistant depression, assessing tolerability and adverse effects of combining psilocybin with risperidone. This pharmacology strategy, exploring neurotransmitter receptor influence on behavior, seeks to block the psychedelic experience using risperidone. Participants receive psilocybin (25mg) plus risperidone (1mg), psilocybin plus placebo, or placebo plus risperidone, alongside psychology support. This medicine, involving such alkaloids, could expand access to psychedelics and drug studies, offering a novel antidepressant.
Abstract
Background Randomised controlled trials (RCTs) of psilocybin have reported large antidepressant effects in adults with major depressive disorder an...
A systematic review to assess the use of psilocybin in the treatment of headaches
European Psychiatry – March 01, 2023
Summary
Remarkably, psilocybin, a naturally occurring hallucinogen, extended headache remission periods for 91% of participants across eight studies. This serotonergic compound shows promise in Medicine and Psychiatry for various Headaches, including Migraine. Macrodosing offered 12.3% more pain reduction than microdosing. While 18% experienced hallucinations, and some temporary distress (5.3% microdosing, 14.1% macrodosing), these Psychedelics and Drug Studies highlight a novel approach. This field of Complementary and Alternative Medicine, involving Chemical synthesis and alkaloids, presents new avenues in Psychology.
Abstract
Introduction Psilocybin is a naturally occurring psychedelic compound whose effects have been seen in studies for treatment of depression, anxiety ...
Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study.
Journal of affective disorders – February 01, 2025
Summary
Psilocybin's mental health benefits may vary across racial groups, according to a large online survey tracking real-world psychedelic use. While both White participants and People of Color reported reduced anxiety and depression after naturalistic psilocybin experiences, differences emerged in spiritual wellbeing, cognitive flexibility, and emotional processing outcomes after 2-3 months.
Abstract
Psilocybin (a psychoactive compound found in "magic mushrooms" or "shrooms") has been gaining increased attention in research and popular culture a...
A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression
Psychedelic Medicine – October 28, 2022
Summary
Compelling news for Mental Health Research Topics: Psilocybin therapy for major depressive disorder significantly outperformed escitalopram on key measures, according to a reanalysis involving 59 patients. In Psychiatry and Clinical psychology, new findings reveal extremely strong evidence for psilocybin's superiority on the Hamd scale. This insight from Psychedelics and Drug Studies shows the psychedelic treatment also demonstrated moderate evidence of clinically meaningful superiority on other scales. Overall, psilocybin proved noninferior to escitalopram for the Treatment of Major Depression.
Abstract
Background: A trial of psilocybin (COMP360) versus escitalopram for major depressive disorder (MDD) was reported as negative, as there was no signi...
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change.
Journal of affective disorders – August 01, 2023
Summary
Psilocybin therapy shows promise in treating major depressive disorder by helping people face rather than avoid difficult emotions. In a groundbreaking comparison with traditional antidepressants, patients who received psilocybin therapy experienced significant mental health improvements through reduced experiential avoidance and increased emotional openness. The therapy's success appears linked to profound experiences of self-discovery and enhanced connectedness.
Abstract
Psilocybin therapy is receiving attention as a mental health intervention with transdiagnostic potential. In line with psychotherapeutic research, ...
Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical Population
OpenAlex – May 29, 2025
Summary
A single dose of the hallucinogen psilocybin profoundly shifted personality, reducing neuroticism and boosting extraversion in a non-clinical population. Among 48 participants, 33 psilocybin dosing sessions revealed notable psychological changes, including increased mindfulness and connectedness, observed one week later. Psilocybin also induced stronger mystical experiences than MDMA, suggesting its unique influence on neurotransmitter receptors and subsequent behavior. These findings from psychedelics and drug studies offer insights for clinical psychology and psychotherapists exploring this chemically synthesized alkaloid for mental well-being.
Abstract
Abstract Objective Despite many decades of experimental studies and clinical trials involving a variety of psychedelic agents, we still lack a comp...
Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression
JAMA Network Open – July 30, 2025
Summary
Psilocybin’s impressive antidepressant effects for Major depressive disorder may be over-estimated. A meta-analysis of 17 Randomized controlled trials (4960 patients) comparing Psilocybin, Serotonin reuptake inhibitors like Fluoxetine, and esketamine for Treatment of Major Depression and Treatment-resistant depression, revealed control groups in psilocybin clinical trials improved less. Their depression rating scale scores improved by an effect size of 0.50, versus 1.00 for antidepressant SSRI controls and 1.12 for esketamine controls. This finding is crucial for Psychiatry and Psychedelics and Drug Studies.
Abstract
Importance Psilocybin has demonstrated rapid and sustained antidepressant efficacy, with acute-phase effect sizes often more than double those for ...
The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action
Frontiers in Pharmacology – December 03, 2020
Summary
Psilocybin, a psychedelic with antidepressant potential, significantly alters sleep architecture. In a study of 20 healthy volunteers (10 women), psilocybin prolonged rapid eye movement (REM) sleep latency and showed a trend towards decreased overall REM sleep duration. Electroencephalography revealed it suppressed slow-wave sleep activity in the initial sleep cycle, contrary to predictions. Non-rapid eye movement sleep remained unchanged. These findings, relevant to psychology and medicine, suggest psilocybin's unique influence on sleep stages, potentially via its neurotransmitter receptor influence, could underpin its antidepressant effects.
Abstract
Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may interact with psilocybin’s antidepressant properties like...
Psilocybin decelerates cellular senescence
OpenAlex – June 27, 2023
Summary
A compelling finding reveals psilocybin, a potent hallucinogen, may decelerate cellular aging. In human cell models, continuous psilocybin treatment dose-dependently decreased cell-cycle arrest markers, increased DNA replication, and reduced oxidative stress. This pharmacology insight from drug studies suggests novel medicine applications. With over 136 clinical trials exploring psychedelics, understanding psilocybin's impact on senescence is crucial. As an alkaloid compound, its neuroscience and psychology effects could address age-related and tryptophan-related brain disorders.
Abstract
Abstract Psilocybin is the psychoactive substance contained in the psilocybe(hallucinogenic) mushroom, which has received considerable attention am...
Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions
Psychedelic Medicine – May 16, 2025
Summary
Psilocybin significantly transformed the spiritual lives of clergy, with 96% reporting at least one experience as among their top five most spiritually significant moments. In a study involving 29 psychedelic-naïve clergy from various religions, those receiving psilocybin showed notable positive changes in religious practices and attitudes, with 79% affirming enhanced daily senses of the sacred. Remarkably, 42% rated an experience as the most profound of their lives. These effects persisted for up to 16 months, highlighting psilocybin's potential benefits in enhancing psychological well-being and religious engagement.
Abstract
Background: Although historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and relig...